| Product Description | IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity In Vitro IZCZ-3 (2.1 μM-15.9 μM; 24 hours) significantly inhibits SiHa, HeLa, Huh7, and A375 cancer cell proliferation (IC 50 s of 3.3, 2.1，4.1, and 4.2 μM, respectively). IZCZ-3 induces only weak growth inhibition in the BJ fibroblasts (IC 50 =15.9 μM) and mouse mesangial cells (IC 50 =15.6 μM), suggesting that IZCZ-3 is more effective against cancer cells than against c-MYC-independent normal cells. IZCZ-3 (0-5 μM; 12 hours) induces an apparent accumulation of cells in the G0/G1 phase in SiHa cells in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SiHa, HeLa, Huh7, and A375 cancer cells (with overexpression of c-MYC protein) and in normal BJ fibroblasts and primary cultured mouse mesangial cells (with relatively low expression of c-MYC protein). Concentration: 2.1 μM-15.9 μM Incubation Time: 24 hours Result: IC 50 s of 3.3, 2.1，4.1, and 4.2 μM for SiHa, HeLa, Huh7, and A375 cancer cells; IC 50 s of 15.9 μM and 15.6 μM for BJ fibroblasts and mouse mesangial cells. Cell Cycle AnalysisCell Line: SiHa cells Concentration: 0, 1.25, 2.5, and 5 μM Incubation Time: 12 hours Result: Induced an apparent accumulation of cells in the G0/G1 phase (increasing from 61% to 70%) in a dose-dependent manner. In Vivo IZCZ-3 (20, 10, and 5 mg/kg; intraperitoneally; every other day for 24 days) inhibits tumor growth in BALB/c nude mice with SiHa human cervical squamous cancer xenograft . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c nude mice (5 weeks old) bearing SiHa human cervical squamous cancer xenograft model Dosage: 20, 10, and 5 mg/kg Administration: Treated intraperitoneally; every other day for 24 days Result: Treatment with 20, 10, and 5 mg/kg resulted in a significant reduction in tumor weight with tumor growth inhibition (TGI) of 69%, 64%, and 57%, respectively. Displayed time-dependent inhibition of tumor growth. Form:Solid IC50& Target:c-MYC transcription |
|---|
